Therapeutic Update

IntraBio Inc. is pleased to announce the Pivotal Trial IB1001-301, *"Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study"* is **active and recruiting** patients 4 years and older in Australia, Europe, the United Kingdom, and United States.

Since enrolment began September 2022, over 30% of patients have been recruited. Given the level of interest in the study, it is expected that the trial will enroll very quickly, and that recruitment will be completed by December 2022.

Patients and families who are interested in learning more about the trial, including the eligibility criteria and enrolment process, are therefore encouraged to contact their prospective study site (see site details listed below).

A brief summary of the eligibility criteria, trial design, and trial sites is provided below. For the complete enrolment criteria, as well as details regarding the study assessments, multinational clinical trial sites, etc., please visit ClinicalTrials.Gov (NCT05163288).

IB1001-301 OVERVIEW

Eligibility Criteria

Patients aged 4 years + may be eligible for recruitment at all trial sites. Patients are required to have neurological symptoms and cannot be using any other investigational agent (including investigational drugs in expanded access programs). Patients are permitted to use a stable dose of miglustat.

IB1001-301 Study Design

IB1001-301 is a multinational, randomized, placebo-controlled, double-blinded, crossover Phase III study. Patients will receive both IB1001 (orally-administered sachet) and a matching Placebo over the course of the study.

Patients will be assessed at 6 study visits during three study periods: a baseline period (approximately 14 -21 days), the first intervention period ("Period I"; approximately 84 -91 days), and the second intervention period ("Period II"; approximately 84 -91 days). Patients will be assessed twice during each intervention period (**Figure 1**).



Figure 1: Study Schema for Naïve patients.

Prohibited Medications: Patients using Tanganil (or other forms of N-acetyl-leucine not provided in IB1001-301) will be required to stop taking the medicine ("washout") for 6-weeks prior to screening (Visit 1) and must remain off Tanganil /other forms of N-acetyl-leucine throughout the duration of the trial.

Randomization: At **Visit 2** (Baseline 2), patients will be randomly assigned (1:1) to two randomization sequences:

- **Sequence 1**: Starting **Visit 2** (Baseline 2), patients will receive IB1001 during Period I (for approximately 84 days). At the end of Period I (Visit 4), the patient will "crossover" and immediately crossover receive placebo during Period II (for approximately 84 days).
- **Sequence 2**: Starting **Visit 2** (Baseline 2), patients will receive placebo during Period I ((for approximately 84 days). At the end of Period I (Visit 4), patients will "crossover" and immediately receive IB1001 during Period II (for approximately 84 days).

Treatment: During the trial, every patient will receive approximately 12-weeks of treatment with IB1001, and 12-weeks of placebo. Patients, their family, and the study team will not know when they are on treatment with IB1001 or placebo.

Study Assessments: Standard functional assessments (e.g., SARA, SCAFI, NPC-CSS, mDRS), will be performed, as well as quality of life questionnaires. There are no invasive procedures (i.e., lumbar punctures). Blood and urine samples will be collected, and physical examinations and 12-lead ECGs will be performed.

Extension Phase

Patients who complete the study (Visit 6) can (if their Principal Investigator (PI) determines it is in their best interest) participate in an open-label extension phase, where patients will receive treatment with IB1001 for a minimum of 1-year.

IB1001-301 TRIAL SITES

AUSTRALIA

The Royal Melbourne Hospital
PI: Mark Walterfang, MD
Email: mark.walterfang@gmail.com
Additional Contact: Mandy Whitechurch
Email: mandy@npcd.org.au

CZECH REPUBLIC

First Faculty of Medicine, Charles University Hospital Prague
PI: Stella Mazurová, MD, PhD
Email: stella.mazurova@vfn.cz

GERMANY

Ludwig Maximilian University of Munich
PI: Susanne Schneider, MD
Email: Susanne.Schneider@med.uni-muenchen.de

University of Giessen
PI: Kyriakos Martakis, MD
Email: Kyriakos.Martakis@paediat.med.uni-giessen.de

University Hospital Münster
PI: Thorsten Marquardt, MD
Contact: Anja Wolf
Email: Anja.Wolf@ukmuenster.de

University of Hamburg
PI: Nicole Muschol, MD
Email: muschol@uke.de

SphinCS – Institute of Clinical Science in LSD
PI: Eugen Mengel, MD
Email: info@sphincs.de

THE NETHERLANDS

Amsterdam UMC
PI: Marian Brands, MD
Email: m.m.brands@amsterdamumc.nl

SWITZERLAND

University Hospital Bern Inselspital
PI: Tatiana Bremova-Ertl, MD, PhD
Email: tatiana.bremova-ertl@insel.ch

SLOVAKIA

Comenius University in Bratislava
PI: Miriam Koníková, MUDr, PhD
Contact: Katarína Cichovská
Email: katarina.cichovska@dfnsp.sk

UNITED STATES

The Mayo Clinic (Rochester, MN)
PI: Antony Fine, MD
Contact: Bridget Neja
Email: Neja.bridget@mayo.edu

Emory University
PI: William Wilcox, MD
Contact: Ami Rosen
Email: arosen3@emory.edu

UNITED KINGDOM

Great Ormond Street Hospital
Trial Site for Patients Aged 4 – 17 Years
PI: Paul Gissen, MD
Contact: Olivia Rosie-Wilkinson
Email: Olivia.Rosie-Wilkinson@gosh.nhs.uk

Royal Free London NHS Foundation Trust
Trial Site for Patients Aged 13 Years +
PI: Uma Ramaswami, MD
Contact: Masoud Kazemi
Email: masoud.kazemi@nhs.net

Royal Manchester Children's Hospital
Trial Site for Patients Aged 4 – 17 Years
PI: Simon Jones, MD
Contact: Laura Crowther
Email: laura.crowther@mft.nhs.uk

Salford Royal NHS Foundation Trust
Trial Site for Patients Aged 18 Years +
PI: Reena Sharma, MD
Contact: Marie Meehan
Email: Marie.Meehan@srft.nhs.uk

If you have any additional questions on the study/recruitment, please contact:

Taylor Fields
Chief Product Development Officer & Senior Vice-President, IntraBio
Email: tfields@intrabio.com